Analysts Are Bullish on These Healthcare Stocks: Teva Pharmaceutical (TEVA), Aquestive Therapeutics (AQST)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Teva Pharmaceutical (TEVA – Research Report), Aquestive Therapeutics (AQST – Research Report) and Enliven Therapeutics (ELVN – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Teva Pharmaceutical (TEVA)
Piper Sandler analyst David Amsellem reiterated a Buy rating on Teva Pharmaceutical today and set a price target of $41.00. The company’s shares closed last Tuesday at $32.28.
According to TipRanks.com, Amsellem is a 4-star analyst with an average return of
Teva Pharmaceutical has an analyst consensus of Strong Buy, with a price target consensus of $40.38, a 23.0% upside from current levels. In a report issued on February 18, Scotiabank also maintained a Buy rating on the stock with a $40.00 price target.
See the top stocks recommended by analysts >>
Aquestive Therapeutics (AQST)
In a report released today, Francois Brisebois from LifeSci Capital reiterated a Buy rating on Aquestive Therapeutics, with a price target of $9.00. The company’s shares closed last Tuesday at $4.12.
According to TipRanks.com, Brisebois is a 2-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aquestive Therapeutics with a $9.60 average price target, which is a 134.1% upside from current levels. In a report issued on March 2, Cantor Fitzgerald also maintained a Buy rating on the stock with a $11.00 price target.
Enliven Therapeutics (ELVN)
Goldman Sachs analyst Salveen Richter maintained a Buy rating on Enliven Therapeutics yesterday and set a price target of $39.00. The company’s shares closed last Tuesday at $28.75, close to its 52-week high of $30.03.
According to TipRanks.com, Richter is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Enliven Therapeutics with a $37.67 average price target, which is a 31.4% upside from current levels. In a report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $39.00 price target.
